Shanghai Institute of Material Medical Chinese Academy of Sciences

Biography

XIE Cen, Ph.D., Principal Investigator of Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Dr. XIE was graduated from SIMM in 2013 with doctoral degree and had a post-doctoral training in National Institutes of Health (NIH) from 2013 to 2018. In Oct 2018, Dr. XIE was appointed as Principal Investigator and project leader of SIMM. Her current research interest is mainly focused on the metabolic diseases and the discovery of novel therapeutic strategies for obesity, non-alcoholic fat liver disease, diabetes, and cancer. She applied integrative multi-omics approaches to tackle the question of cross-talking between micro-environment of intestine and liver or other organs in host, to investigate the mechanism of association between intestine and related diseases, to discover the new drug targets and innovative medical therapies. Dr. XIE has published more than 50 papers, and many are among the top of journals in the fields, including but not limited to Nature Medicine (2), Cell Metabolism, Nature Communications, Diabetes as first or co-first author, and those works have been cited more than 1000 times. Dr. XIE also had five patents based on her research and one has already been authorized.

Education

2008.9-2013.7 Ph.D., Pharmaceutical Analysis, University of Chinese Academy of Sciences (Shanghai Institute of Materia Medica)

2004.9-2008.7 B.S., Pharmaceutics, Zhejiang University

Work Experience

2018.10- Principal investigator, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

2013.10-2018.10 Postdoctoral fellow, National Cancer Institute, NIH

2013.7-2013.9 Assistant researcher, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Research Directions

Pharmacology in metabolic diseases including obesity, non-alcoholic fat liver disease, diabetes and cancer, new drug target discovery and new drug development.

Grants & Research Projects

Achievements

1.Discovered the mechanism how FXR regulates lipid metabolism in the intestine, and identified a specific inhibitor for intestinal FXR as a drug candidate for the treatment of metabolic diseases (Nat Med, 2018; Diabetes, 2017; Nat Commun, 2015).

2.Discovered the gut microbiota activate the intestinal HIF2 signaling pathway in obesity, and identified intestinal HIF2 as a novel drug target for metabolic diseases (Nat Med, 2017).

3.Discovered a new mechanism for intermittent fasting improving metabolic dysfunctions by shaping the gut microbiota and activing white adipose beiging (Cell Metab, 2017).

morefold

Social Titles

morefold

Awards & Honors

morefold

Pubilcations

Full Publication List

Selected Publications

1.Sun L#, Xie C#, Wang G#, Wu Y#, Wu Q, Wang X, Liu J, Deng Y, Xia J, Chen B, Zhang S, Yun C, Lian G, Zhang X, Zhang H, Bisson WH, Shi J, Gao X, Ge P, Liu C, Krausz KW, Nichols RG, Cai J, Rimal B, Patterson AD, Wang X, Gonzalez FJ, Jiang C. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018.

2.Xie C, Yagai T, Luo Y, Liang X, Chen T, Wang Q, Sun D, Zhao J, Ramakrishnan SK, Sun L, Jiang C, Xue X, Tian Y, Krausz KW, Patterson AD, Liu Y, Shah YM, Wu Y, Jiang C and Gonzalez FJ. Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis. Nat Med. 2017, 23: 1298-1308.

3.Li G#, Xie C#, Lu S, Nichols RG, Tian Y, Li L, Ma Y, Brocker C, Yan T, Krausz KW, Xiang R, Gavrilova O, Patterson AD and Gonzalez FJ. Intermittent fasting promotes browning of white adipose tissue and improves metabolic syndrome via shaping the gut microbiota. Cell Metab. 2017, 26: 672-685.e4.

4.Xie C, Jiang C, Shi J, Gao X, Sun D, Sun L, Wang T, Takahashi S, Anitha M, Krausz KW, Patterson AD and Gonzalez FJ. An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice. Diabetes. 2017, 66: 613-626.

5.Jiang C#, Xie C#, Lv Y, Li J, Krausz KW, Shi J, Brocker CN, Desai D, Amin SG, Bisson WH, Liu Y, Gavrilova O, Patterson AD and Gonzalez FJ. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015, 6: 10166.

morefold